What is Veracyte, Inc. worth?
With the base-case assumptions below, a discounted cash flow model on Veracyte, Inc.'s reported free cash flow gives $54.41 per share. The share price was $24.17 on November 10, 2026, 56% below that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 10.0% | 10.0% | $34.03 | +41% |
| Base | 15.0% | 9.0% | $54.41 | +125% |
| Bull | 20.0% | 8.0% | $92.34 | +282% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $69.83 | $74.64 | $80.52 | $87.87 | $97.32 |
| 8.0% | $58.24 | $61.36 | $65.05 | $69.47 | $74.88 |
| 9.0% | $49.81 | $51.94 | $54.41 | $57.28 | $60.67 |
| 10.0% | $43.42 | $44.93 | $46.65 | $48.62 | $50.88 |
| 11.0% | $38.42 | $39.53 | $40.77 | $42.17 | $43.75 |
Where the presets come from
Base: years 1 to 5 grow at Veracyte, Inc.'s revenue growth rate over the last 5 fiscal years (34.5% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions